MAYZENT Resources

RESOURCES TO HELP YOU LEARN MORE ABOUT MAYZENT®
AND GET YOUR PATIENTS STARTED




MAYZENT RESOURCES

For HCPs and Office Staff

Submitting the Start Form automatically enrolls patients in Alongside TM MAYZENT®, and helps them get started on treatment.

Onboarding Brochure

This piece explains how to get your patients started on MAYZENT in just 2 steps—assessments and initiation.

DOWNLOAD
This brochure details the proven experience of MAYZENT in patients with progressing RMS and encourages choosing MAYZENT earlier to stay ahead of progression.

Choose MAYZENT Brochure

This brochure details the proven experience of MAYZENT in patients with progressing RMS and encourages choosing MAYZENT earlier to stay ahead of progression.

DOWNLOAD
Submitting the Start Form automatically enrolls patients in Alongside TM MAYZENT®, and helps them get started on treatment.

Start Form

Submitting the Start Form automatically enrolls patients in AlongsideTM MAYZENT, and helps them get started on treatment.

DOWNLOAD
MAYZENT Authorization & Appeals Kit

Authorization & Appeals Kit

This tool kit explains how to navigate the insurance coverage process; it includes sample letters and checklists to help you ensure a complete submission.

DOWNLOAD
Sample Appeal Letter

Sample Appeal Letter

If a patient is denied coverage, you may be required to explain the clinical rationale for prescribing MAYZENT. This letter addresses each specific reason given for the denial.

DOWNLOAD
Sample Medical Necessity Letter

Sample Medical Necessity Letter

You may need to prepare this letter to document the medical need for MAYZENT based on the patient’s specific medical history and diagnosis.

DOWNLOAD
Sample Formulary Exception Request Letter

Sample Formulary Exception Request Letter

For health plans that list MAYZENT as nonformulary or not covered/NDC block, you may be asked to submit a letter like this, depending on the health plan’s requirements.

DOWNLOAD

For Patients

For Patients

This comprehensive piece provides important information on treatment initiation for both GILENYA and MAYZENT

Patient Brochure

This brochure can answer your patients’ questions about MAYZENT—from getting started to information about efficacy and side effects.

DOWNLOAD
Getting Started on Treatment Brochure. A step-by-step guide to titration, storage and handling, and how to get support through Alongside MAYZENT

Getting Started on Treatment Brochure

A step-by-step guide to titration, storage and handling, and how to get support through Alongside MAYZENT.

DOWNLOAD

FOR PATIENTS

For patient-friendly links and easy-to-download materials on MS and MAYZENT, patients can
visit the resources page on mayzent.com.

FOR PATIENTS

For patient-friendly links and easy-to-download materials on MS and MAYZENT, patients can visit the resources page on mayzent.com.

TELEMEDICINE RESOURCES

Tips and Tools

If you are seeing patients remotely, below are some helpful resources for both you and your patients.

This comprehensive piece provides important information on treatment initiation for both GILENYA and MAYZENT

For Patients: Digital Checklist

A downloadable aid to help patients have a more engaging virtual visit, along with some technical tips.

DOWNLOAD
Telemedicine

Tips for getting the most out of telemedicine from experts and peers in the industry.

The Northwest Regional Telehealth Resource Center’s Quick Start Guide to Telehealth

DOWNLOAD

The South Central Telehealth Resource Center’s Telehealth Etiquette Series

VIEW

The American Academy of Neurology’s COVID-19 Resource Center

VISIT

Health and Human Services Telehealth Resource for Providers

VISIT

HCP, health care professional; MOA, mechanism of action; MOD, mechanism of disease; MS, multiple sclerosis; RMS, relapsing MS.

Back to top

Indication and Important Safety Information

COLLAPSE

EXPAND

IMPORTANT SAFETY INFORMATION

Contraindications

  • Patients with a CYP2C9*3/*3 genotype

  • In the last 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure

  • Presence of Mobitz type II second-degree, third-degree atrioventricular block, or sick sinus syndrome, unless patient has a functioning pacemaker

INDICATION

MAYZENT® (siponimod) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Infections: MAYZENT may increase risk of infections with some that are serious in nature. Life-threatening and rare fatal infections have occurred.

Before starting MAYZENT, review a recent complete blood count (CBC) (ie, within 6 months or after discontinuation of prior therapy). Delay initiation of treatment in patients with severe active infections until resolved. Employ effective treatments and monitor patients with symptoms of infection while on therapy. Consider discontinuing treatment if patient develops a serious infection.

Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another sphingosine 1-phosphate (S1P) receptor modulator. Rare cases of CM have occurred with MAYZENT. If CM is suspected, MAYZENT should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.

No cases of progressive multifocal leukoencephalopathy (PML) were reported in MAYZENT clinical trials; however, they have been observed in patients treated with another S1P receptor modulator and other multiple sclerosis (MS) therapies. If PML is suspected, MAYZENT should be discontinued.

Cases of herpes viral infection, including cases of meningitis or meningoencephalitis caused by VZV reactivation, have been reported. Patients without a confirmed history of varicella zoster virus (VZV) or without vaccination should be tested for antibodies before starting MAYZENT. If VZV antibodies are not present or detected, then VZV immunization is recommended and MAYZENT should be initiated 4 weeks after vaccination.

Use of live vaccines should be avoided while taking MAYZENT and for 4 weeks after stopping treatment.

Caution should be used when combining treatment (ie, anti-neoplastic, immune-modulating, or immunosuppressive therapies) due to additive immune system effects.

Macular Edema: In most cases, macular edema occurred within 4 months of therapy. Patients with history of uveitis or diabetes are at an increased risk. Before starting treatment, an ophthalmic evaluation of the fundus, including the macula, is recommended and at any time if there is a change in vision. The use of MAYZENT in patients with macular edema has not been evaluated; the potential risks and benefits to the individual patient should be considered.

Bradyarrhythmia and Atrioventricular Conduction Delays: Prior to initiation of MAYZENT, an ECG should be obtained to determine if preexisting cardiac conduction abnormalities are present. In all patients, a dose titration is recommended for initiation of MAYZENT treatment to help reduce cardiac effects.

MAYZENT was not studied in patients who had:

Reinitiation of treatment (initial dose titration, monitoring effects on heart rate and AV conduction [ie, ECG]) should apply if ≥4 consecutive daily doses are missed.

Respiratory Effects: MAYZENT may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy if clinically warranted.

Liver Injury: Elevation of transaminases may occur in patients taking MAYZENT. Before starting treatment, obtain liver transaminase and bilirubin levels. Closely monitor patients with severe hepatic impairment. Patients who develop symptoms suggestive of hepatic dysfunction should have liver enzymes checked, and MAYZENT should be discontinued if significant liver injury is confirmed.

Cutaneous Malignancies: The risk of cutaneous malignancies (including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma) is increased in patients treated with S1P modulators. Use of MAYZENT has been associated with an increased risk of BCC and SCC. Cases of other cutaneous malignancies, including melanoma, have also been reported in patients treated with MAYZENT and in patients treated with another S1P modulator.

Skin examinations are recommended at the start of treatment and periodically thereafter for all patients. Monitor for suspicious skin lesions and promptly evaluate any that are observed. Exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with high protection factor. Concomitant phototherapy with UV-B radiation or PUVA-photochemotherapy is not recommended.

Increased Blood Pressure: Increase in systolic and diastolic pressure was observed about 1 month after initiation of treatment and persisted with continued treatment. During therapy, blood pressure should be monitored and managed appropriately.

Fetal Risk: Based on animal studies, MAYZENT may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during and for 10 days after stopping MAYZENT therapy. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to MAYZENT during pregnancy. Healthcare providers are encouraged to enroll pregnant patients, or pregnant women may register themselves in the MotherToBaby Pregnancy Study in Multiple Sclerosis by calling 1-877-311-8972, sending an email to MotherToBaby@health.ucsd.edu, or visiting www.mothertobaby.org/join-study.

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported in patients receiving an S1P receptor modulator. Such events have not been reported for patients treated with MAYZENT in clinical trials. If patients develop any unexpected neurological or psychiatric symptoms, a prompt evaluation should be considered. If PRES is suspected, MAYZENT should be discontinued.

Unintended Additive Immunosuppressive Effects From Prior Treatment or After Stopping MAYZENT: When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects.

Initiating treatment with MAYZENT after treatment with alemtuzumab is not recommended.

After stopping MAYZENT therapy, siponimod remains in the blood for up to 10 days. Starting other therapies during this interval will result in concomitant exposure to siponimod.

Lymphocyte counts returned to the normal range in 90% of patients within 10 days of stopping therapy. However, residual pharmacodynamic effects, such as lowering effects on peripheral lymphocyte count, may persist for up to 3-4 weeks after the last dose. Use of immunosuppressants within this period may lead to an additive effect on the immune system, and therefore, caution should be applied 3-4 weeks after the last dose of MAYZENT.

Severe Increase in Disability After Stopping MAYZENT: Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of an S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping MAYZENT treatment, thus patients should be monitored upon discontinuation.

Most Common Adverse Reactions: Most common adverse reactions (>10%) are headache, hypertension, and transaminase increases.

INDICATION

MAYZENT® (siponimod) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Please click here for full Prescribing Information, including Medication Guide.